Esophagogastric Junction Carcinoma
📧 Sign up to get email alerts when something new happens for Esophagogastric Junction Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-02-26Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study [Phase 3]
Phase 3 trial comparing pembrolizumab to investigator's choice chemotherapy in advanced esophageal/esophagogastric junction carcinoma after …
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) [Phase 3]
Phase 3 trial of pembrolizumab vs investigator's choice for advanced esophageal/esophagogastric junction carcinoma after first-line therapy;…
-
CLINICAL_TRIALS trial_result · 2019-07-17Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) [Phase 2]
Phase 2 trial of pembrolizumab in previously treated advanced esophageal/eg junction carcinoma completed with results posted in 2019.